{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Welireg"},{"type":"CodeName","name":"PT2977"},{"type":"CodeName","name":"MK6482"},{"type":"Synonym","name":"HIF-2alpha inhibitor PT2977"},{"type":"CodeName","name":"MK 6482"},{"type":"CASRegistryName","name":"1672668-24-4"},{"type":"CodeName","name":"MK-6482"}],"definition":{"html":"An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.","text":"An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/belzutifan","text":"Belzutifan"},"nciConceptId":"C135627","nciConceptName":"Belzutifan","termId":788947,"name":"belzutifan","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"belzutifan"}],"links":null}